Loading...
NASDAQ: AADI
Aadi Bioscience, Inc.
Healthcare · Biotechnology
Market Cap
$94.89M
52w High
$3.81
52w Low
$1.21
P/E
-12.70
Volume
62.61K
Outstanding Shares
46.29M
Company profile
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
CEODavid J. Lennon
SectorHealthcare
IndustryBiotechnology
Employees53
IPO dateFeb 16, 2018
Valuation
Forward P/E—
EV/EBITDA-8.92
Enterprise value$1.02B
Stock splits
Aug 27, 20211:15
Aug 18, 20212:1
Profitability & growth
Revenue growth-100%
Gross margin89.28%▼100.00%vs FY2024
Operating margin-1,601.12%▼516.71%vs FY2024
ROE-15.11%▲87.55%vs FY2024
Analyst consensus
RatingBuy
Target price$1.63▼20.49%
3
Buy
3
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 12, 2026
View
EPS
Actual vs estimate by quarter
Q3'25
ActualEst.
-$0.76
—
Q4'25
ActualEst.
-$0.26
—
Q1'26
ActualEst.
-$0.04
—
Q2FY24
Next Est.
—
Revenue
Actual vs estimate by quarter
Q3'25
ActualEst.
—
—
Q4'25
ActualEst.
—
—
Q1'26
ActualEst.
—
—
Q2FY24
Next Est.
—